Company news

Alector, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia

July 27, 2020

Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia

July 23, 2020

Alector to Present Data from the AL001 Phase 2 Open-Label Study in Frontotemporal Dementia at the 2020 Alzheimer’s Association International Conference

July 20, 2020

Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medicine

June 24, 2020

Alector to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

June 2, 2020

Alector Reports 2020 First Quarter Financial Results and Business Highlights

May 12, 2020

Alector to Present at the Bank of America Securities Virtual Health Care Conference

May 6, 2020

Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China

March 24, 2020

Alector Reports 2019 Fourth Quarter and Full Year Financial Results and Business Highlights

March 23, 2020

Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors

March 22, 2020

Alector to Present at the Cowen 40th Annual Health Care Conference

February 23, 2020

Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia

February 4, 2020

Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

February 2, 2020

Alector Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering

January 30, 2020

Alector Announces Upsizing and Pricing of Public Offering

January 28, 2020

Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer’s Disease Patients

January 27, 2020

Alector to Present at the J.P. Morgan 38th Annual Healthcare Conference

January 7, 2020

Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

January 5, 2020

Alector Added to the NASDAQ Biotechnology Index

December 19, 2019

Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D Day

December 12, 2019

Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee

December 12, 2019

Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating Officer

December 10, 2019

Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

December 5, 2019

Alector Announces FDA Fast Track Designation Granted to AL001 for the Treatment of Patients with Frontotemporal Dementia

December 4, 2019

Alector to Host R&D Day on December 13, 2019

December 3, 2019

Alector to Present at the Jefferies 2019 London Healthcare Conference

November 13, 2019

Alector Reports Recent Business Highlights and Third Quarter 2019 Financial Results

November 11, 2019

Alector Initiates Phase 2 Trial of AL001 in Patients with Frontotemporal Dementia

September 8, 2019

← Newer news releases

Calls

Decks